Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Sigma (ASX:SIG) shares sink on ACCC Chemist Warehouse merger concerns

The Sigma Healthcare Ltd (ASX:SIG) share price is down 7% as the market digests the ACCC's concerns about the Chemist Warehouse merger.

The Sigma Healthcare Ltd (ASX: SIG) share price is down 7% as the market digests the ACCC’s concerns about the Chemist Warehouse merger.

In December 2023, Sigma Healthcare announced it was planning to merge with Chemist Warehouse.

ACCC shares Chemist Warehouse concerns

The Australian Competition and Consumer Commission (ACCC) noted this proposal is a “major structural change” for the pharmacy sector, involving the largest pharmacy chain by revenue merger with a key wholesaler to thousands of independent pharmacies that compete against Chemist Warehouse.

The ACCC said it had identified a “range of preliminary competition concerns, including at the retail level”.

Australia’s competition regulator now wants to hear from interested parties, including rival pharmacies, as it continues this review.

The ACCC emphasised it’s focused on whether this deal would impact competition. It’s also concerned that the merger may harm pharmacies currently supplied by Sigma, leading to a “substantial lessening of competition in pharmacy retail”.

A company that’s vertically-integrated across multiple levels of the pharmacy supply chain could “raise barriers to rivals expanding or entering, which may lessen competition”.

Currently, the ACCC says, Sigma is incentivised to maximise wholesale sales. But after the proposed transaction, the newly merged business “may have the ability and incentive to favour Chemist Warehouse stores or worsen terms to non-Chemist Warehouse banner stores, raising their costs and rendering them less competitive.”

Another concern for the ACCC is that Chemist Warehouse may access and use commercially sensitive data relating to pharmacies supplied by Sigma, harming competition.

ACCC Commissioner Stephen Ridgeway said:

This lessening of competition may lead to reduced service quality for goods and services provided in pharmacies as well as higher prices for consumers. The transaction may also weaken the competitiveness of the different product and services offered by Sigma’s banner pharmacies.

Sigma response

Sigma said in an ASX announcement that the issues identified by the ACCC are not “unexpected for a proposed transaction of this complexity” and noted the views are “preliminary” on “potential issues”,

Chemist Warehouse and Sigma think there are “good arguments” why the proposed merger won’t lessen competition, though didn’t outline them.

The ACCC expects to make a final decision on 5 September 2024, though the timeline can change.

Final thoughts on the Chemist Warehouse merger

While it’s still possible the merger could go ahead, it seems like an uphill challenge with the number of different concerns from the ACCC, and how it has outlined the change could affect other pharmacies and consumers.

I wouldn’t buy Sigma shares right now expecting the deal to go ahead.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content